

Development of cancer cachexia treatment using anti-GFRAL antibody



ONCOLOGY	Candidate
Product Type	Immunoglobulin (mAb)
Indication	1st indication: Cancer cachexia
Target	GFRAL receptor
MoA(Mechanism of Action)	Antagonistic antibody targeting GDF15/GFRAL/RET axis alleviates chemotherapy-induced cachexia
Competitiveness	First In Class
Development Stage	Candidate
Route of Administration	Parenteral-Intravenous